rs763216519
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1PM2PP4
This summary comes from the ClinGen Evidence Repository: This variant, c.876C>G (p.Tyr292Ter), is a nonsense variant that is predicted to result in nonsense mediated decay and lack of gene product. Therefore, PVS1 can be applied. Functional studies, in which the variant was expressed in COS cells revealed no GAA activity in the cells or medium. However, a faint band representing GAA protein was detectable on Western blot (PMID 31510962). As the experiment was done in an in vitro expression system, it is unclear whether any gene product would be made in vivo. This variant was absent in gnomAD v2.1.1, meeting PM2. Two patients with infantile onset Pompe disease from Thailand have been reported (PMID 31510962). The residual GAA activity was provided for one of them, meeting PP4. This patient is compound heterozygous for the variant and c.1003G>A (p.Gly335Arg). The in trans data from this patient was used in the assessment of p.Gly335Arg and is not included here in order to avoid circular logic. The other patient is homozygous, and both parents were confirmed to be carriers, but the residual GAA activity is not available, and this data will not be included. Therefore, PM3 is currently not met. There is a ClinVar entry for this variant (Variation ID: 637958, 0 star review status) with one submitter (an author of this paper) classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PP4. LINK:https://erepo.genome.network/evrepo/ui/classification/CA401363871/MONDO:0009290/010
Frequency
Consequence
NM_000152.5 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GAA | NM_000152.5 | c.876C>G | p.Tyr292Ter | stop_gained | 5/20 | ENST00000302262.8 | NP_000143.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GAA | ENST00000302262.8 | c.876C>G | p.Tyr292Ter | stop_gained | 5/20 | 1 | NM_000152.5 | ENSP00000305692 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 57
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Glycogen storage disease, type II Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing;in vitro | Department of Pediatrics, Division of Medical Genetics, Faculty of Medicine Ramathibodi Hospital, Mahidol University | Jul 10, 2019 | The c.876C>G creates a premature protein product p.Y292* resulting from early termination of protein synthesis. This variant has not been reported in the literature in individuals with GAA-related disease. The c.876C>G (p.Y292*) located at N-terminal of beta-sheet domain, is predicted to eliminate most of the enzyme, including the catalytic domain. In vitro expression analysis of c.876C>G (p.Y292*) indicates that this mutation lead to undetectable GAA activity in both cell lysate and culture medium and prohibited secretion of the precursor form completely. We interpret this variant has been classified as Pathogenic. - |
Pathogenic, reviewed by expert panel | curation | ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel | Oct 05, 2020 | This variant, c.876C>G (p.Tyr292Ter), is a nonsense variant that is predicted to result in nonsense mediated decay and lack of gene product. Therefore, PVS1 can be applied. Functional studies, in which the variant was expressed in COS cells revealed no GAA activity in the cells or medium. However, a faint band representing GAA protein was detectable on Western blot (PMID 31510962). As the experiment was done in an in vitro expression system, it is unclear whether any gene product would be made in vivo. This variant was absent in gnomAD v2.1.1, meeting PM2. Two patients with infantile onset Pompe disease from Thailand have been reported (PMID 31510962). The residual GAA activity was provided for one of them, meeting PP4. This patient is compound heterozygous for the variant and c.1003G>A (p.Gly335Arg). The in trans data from this patient was used in the assessment of p.Gly335Arg and is not included here in order to avoid circular logic. The other patient is homozygous, and both parents were confirmed to be carriers, but the residual GAA activity is not available, and this data will not be included. Therefore, PM3 is currently not met. There is a ClinVar entry for this variant (Variation ID: 637958, 0 star review status) with one submitter (an author of this paper) classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PP4. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at